Find A Research Study
Study Title: Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer
Category: Cancer, General
Currently accepting participants?
Not at this time.
Principal Investigator: Thomas Malpass
Study Coordinator: Kathy Rabena
Phone: (206) 223-6892 Ext.36892
Email: Katherine.Rabena@vmmc.org
What is the Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer study?
Who can participate?
~Patients with recurrent epithelial ovarin, fallopian tube, or primary peritoneal cancer.
~Has received one prior platinum-based chemotherapeutic regimen (containing either carboplatin or cisplatin) for the treatment of primary disease.
~Patient's disease is considered potentially platinum-sensitive.
~Must have atleast one measurable lesion as determined by diagnostic studies including CT or MRI or physical exam.
Ineligibility:
~Pregnant or lactating
~Received morn that 1 prior chemotherapy regimen or a histery of consolidation cytotoxic chemotherapy
~Has brain metasteses
~Received prior treatment with Hymcantin
What do I have to do as a study participant?
Study Summary:
Detailed Study Description:
Study Design: Interventional
Phase of Study: Phase II
Study Type: Interventional
Condition or Study Focus: Ovarian Cancer
Intervention Type: Chemotherapy
Intervention Name: Hymcantin
Gender: Female
Age group: Interventional
Sponsor: GlaxoSmithKline
Other studies in this category include:
Studies currently accepting study participants:
- A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC),
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- AMC047: AIDS-Associated B-Cell Non-Hodgkin's Lymphoma
- Brain Metastases in NSCLC (RTOG 0320)
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Lymphoma (S0313)
- Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212)
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
- PGT307 - Paclitaxel Poliglumex plus Carboplatin for the treatment of non-small cell lung cancer in women.
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Sorafenib vs Placebo for Hepatocellular Carcinoma
- Stage IV Urothelial Cancer
- SWOG S0016
- Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Failed First-Line Sunitinib
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly Topotecan (HyCamtin®) with Bevacizumab (Avastin®) Ovarian, Fallopian tube and/or Peritoneal Cancer
Studies currently not accepting study participants:
- Methylphenidate in Treating Patients With Fatigue Caused by Cancer
- MK0646 for Patients with Advanced Cancer
- Open Label Study of Human Corticotropin-Releasing Factor (hCRF)
- Phase I, oral agent for Advanced Cancers
- Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer